Boston Scientific
As of April 15, 2026, the medical technology landscape is bracing for its most significant transformation in years. Boston Scientific (NYSE:BSX) is moving steadily toward the finalization of its $14.9 billion acquisition of Penumbra, Inc. (NYSE:PEN), a deal that represents the company's largest M&
Boston Scientific
In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN) for approximately $14.9 billion. The deal, priced at $374.00 per share, represents a significant premium for Penumbra shareholders and marks one of
Bank of America
The financial landscape of 2026 has been marked by a return to high-stakes deal-making and intense market fluctuations, and no institution seems more equipped to navigate this era than Bank of America (NYSE:BAC). On April 15, 2026, the banking giant reported a blockbuster first-quarter earnings beat, signaling a decisive
Boston Scientific
On January 15, 2026, the medical technology sector witnessed its most significant seismic shift in years as Boston Scientific Corporation (NYSE:BSX) announced a definitive agreement to acquire Penumbra, Inc. (NYSE:PEN) for an enterprise value of approximately $14.5 billion. This transaction, structured as a mix of 73% cash
Boston Scientific
In a move that has sent shockwaves through the medical technology sector, Boston Scientific (NYSE:BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The deal represents the largest acquisition for Boston Scientific in over two decades, signaling a transformative
Boston Scientific
In a move that has sent shockwaves through the healthcare sector, Boston Scientific (NYSE:BSX) has announced a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The deal, announced in mid-January and currently the talk of Wall Street as we move into February 2026, marks one
Boston Scientific
MARLBOROUGH, Mass. — In a move that has sent shockwaves through the medical technology landscape, Boston Scientific (NYSE: BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra (NYSE: PEN) for an enterprise value of approximately $14.5 billion. The deal, representing Boston Scientific’s largest acquisition in over
Boston Scientific
In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced on January 15, 2026, its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN) for approximately $14.5 billion. The deal represents one of the most significant consolidations in the history of the medical
Boston Scientific
MARLBOROUGH, MA – In a move that has sent shockwaves through the medical device sector, Boston Scientific Corporation (NYSE:BSX) announced today, January 15, 2026, a definitive agreement to acquire Penumbra, Inc. (NYSE:PEN) for approximately $14.5 billion. The blockbuster deal, the largest in the industry since the early 2020s,
Boston Scientific
Boston Scientific (NYSE: BSX) has delivered an exceptional third-quarter 2025 earnings report, significantly surpassing analyst expectations and reinforcing its position as a leading innovator in the medical device industry. The strong performance, highlighted by robust sales growth and an upward revision of full-year guidance, has sent a positive signal to